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Abstract
Background: Veterinary drugs such as clenbuterol (CL) and sulfamethazine (SM2) are low molecular weight (<1000 Da) 
compounds, or haptens, that are difficult to develop immunoassays due to their low immunogenicity. In this study, we 
conjugated the drugs to ovalbumin to increase their immunogenicity for antiserum production in rabbits and 
developed a protein microarray immunoassay for detection of clenbuterol and sulfamethazine. The sensitivity of this 
approach was then compared to traditional ELISA technique.
Results: The artificial antigens were spotted on microarray slides. Standard concentrations of the compounds were 
added to compete with the spotted antigens for binding to the antisera to determine the IC50. Our microarray assay 
showed the IC50 were 39.6 ng/ml for CL and 48.8 ng/ml for SM2, while the traditional competitive indirect-ELISA (ci-
ELISA) showed the IC50 were 190.7 ng/ml for CL and 156.7 ng/ml for SM2. We further validated the two methods with 
CL fortified chicken muscle tissues, and the protein microarray assay showed 90% recovery while the ci-ELISA had 76% 
recovery rate. When tested with CL-fed chicken muscle tissues, the protein microarray assay had higher sensitivity (0.9 
ng/g) than the ci-ELISA (0.1 ng/g) for detection of CL residues.
Conclusions: The protein microarrays showed 4.5 and 3.5 times lower IC50 than the ci-ELISA detection for CL and SM2, 
respectively, suggesting that immunodetection of small molecules with protein microarray is a better approach than 
the traditional ELISA technique.
Background
Veterinary drugs are widely used in modern agricultural
practice for therapeutic and prophylactic purposes.
Unfortunately, illegal and abusive usage of veterinary
drugs can cause long-term and short-term public health
hazard [1]. Monitoring of edible animal products for the
presence of veterinary drug residues is an essential pro-
cess in ensuring the safety of the food supply. The com-
plexity of the biological matrices and the huge variety of
drug residues preclude the use of a single analytical
method. Currently, liquid chromatography (LC) com-
bined with tandem mass spectrometric detection is the
preferred technique in a large majority of all cases for
quantification and confirmation [2-4]. Other chromato-
graphic methods such as high performance liquid chro-
matography (HPLC) can be used for multiple residues
screening, but the need for extensive sample pretreat-
ment, specialized equipment and highly trained person-
nel make most chromatographic methods poorly suited
for screening purposes. Microbial survival assays and
immunoassays are more suitable for screening. However,
microbiological assays are time consuming, and the iden-
tity of the offending compound is not immediately
known. On the other hand, immunochemical detections
such as ELISA have a fast turnaround, there is no need for
any extensive sample preparation, and the compound is
immediately identified. ELISAs are, therefore, one of the
most commonly employed screening methods.
Protein microarray as an emerging technology has
many advantages over the traditional ELISA method. It is
a versatile, miniature and high-throughput platform that
can be adapted for a variety of screening uses. Protein
microarrays are already widely used to perform high
though-put drug screens, to study protein-protein inter-
actions, and have great potential for disease diagnosis
[5,6]. The technology can also be used to detect veteri-
nary drug residues. Here, we describe our protein
microarray immunodetection assay [7,8] for two com-
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monly abused veterinary drugs: clenbuterol (CL) [9] and
sulfamethazine (SM2) [10]. We compared its sensitivity to
traditional ELISA-based method, and tested the applica-
bility of the assay to complex biological material.
Methods
Reagents and chemicals
The following reagents were purchased from Sigma-
Aldrich, St. Louis, MO, USA: clenbuterol (CL), sulfamet-
hazine (SM2), bovine serum albumin (BSA), ovalbumin
(OVA), Freund's adjuvant complete (FCA), Freund's adju-
vant Incomplete (FIA), Tween-20 and N', N-Dimethylfor-
mamide (DMF). Cy3-goat-anti-rabbit IgG, and HRP-
goat-anti-rabbit IgG were purchased from Jackson
ImmunoResearch, West Grove, PA, USA. 3,3'5,5'-
Tetramethyl Benzidine dihydrochloride (TMB) was pur-
chased from Amresco, Inc., Solon, OH, USA.
Hapten-carrier conjugation
The aromatic primary amine on CL and SM2 were acti-
vated by diazotization and coupled to the phenol group of
tyrosine residues on ovalbumin (OVA) as a carrier pro-
tein [11]. The detailed conjugation procedures are as fol-
lows: 10 mg of each hapten were first acidified (CL with
400 μl of 1 M HCl; SM2 with 250 μl 0.5 M H2SO4). Then,
2% NaNO2 was slowly added with stirring. After 1 h, 1 ml
of 0.1 M carbonate buffer solution (pH 9.6) containing 35
mg OVA was added. The pH was maintained between 9
and 9.6 through the periodic addition of 0.5 M NaOH.
The solution was allowed to stir overnight at 4°C. The
conjugated product was dialyzed into PBS for 72 h, with
PBS replacement at 8 h intervals. The synthetic products
were combined with the same volume of sterile 80% glyc-
erol and then frozen at -20°C. The formation of the artifi-
cial antigens was monitored by UV absorbance from 200
to 400 nm (TU-1810 V-spectrophotometer, Beijing
Purkinje General Instruments, Beijing, China). Within
this wavelength range, the haptens, OVA and the respec-
t i v e  c o n j u g a t e s  h a v e  d i s t i n c t  a b s o r b a n c e  p a t t e r n s  a n d
thus could be used to identify the formation of the conju-
gated product.
The efficiency of the diazotization was determined by
the coupling ratios of the haptens to OVA. The conjuga-
tion ratios of CL to OVA and SM2 to OVA are 16:1 and
3:1, respectively.
Antibody Production
One mg of each immunogen (CL-OVA and SM2-OVA)
were diluted with sterile saline and combined with an
equal volume of complete Freund's adjuvant for the initial
subcutaneous injection into New Zealand White Rabbits
(SLAC Laboratory Animals, Shanghai, China). Second
and third injections were mixed with incomplete Freund's
adjuvant, and no adjuvant was used for the forth. The
injections were 15 days apart, and two rabbits were
immunized with each immunogen. Blood was collected
before the start of immunizations as a negative control,
and 10 days after each immunization for titer monitoring.
2 ml of blood was collected each time from the central ear
artery and allowed to clot and retract at 37°C for 2 h and
overnight at 4°C. The blood samples were then centri-
fuged at room temperature for 15 minutes at 3000 rpm
and the sera were decanted into sterile tubes.
Antibody Titer Monitoring
Titers of the polyclonal antibodies against the two immu-
nogens were determined by indirect ELISA. 96 well plates
were coated with CL or SM2 artificial antigens overnight
a t  4 ° C .  T h e  p l a t e s  w e r e  w a s h e d  3  t i m e s  w i t h  P B S T
(0.5%Tween-20 in PBS), and blocked with 150 μl of 0.1%
(w/v) OVA per well at 37°C for 1.5 h. Antisera from each
injection were diluted from 1:200 to 1:25,600 on a two-
fold dilution series and 100 μl were applied to each well.
Undiluted pre-immune sera were also assayed as the neg-
ative control. The plates were incubated at 37°C for 1 h,
washed with PBST, and then incubated with HRP-anti-
rabbit IgG (1:1000 dilution, 100 μl) at 37°C for 1 h. Finally,
TMB (100 μl per well) was added and incubated at 37°C
for 20 min, and 50 μl per well of 2 M H2SO4 was added to
stop the enzymatic reaction. The plates were read with a
ZS-2 microplate reader (Beijing Xin Feng Machine Elec-
tric Technical Instruments, Beijing, China). The final
optical density reading was adjusted for background
absorbance (OD = OD450 nm - OD630 nm).
We could observe an increase in the OD after each
injection, indicating that the titers were rising. The pre-
immune sera showed insignificant amount of absorbance,
implicating that the antisera were specific. We deter-
mined that after four injections, a sufficient titer was
achieved for both immunogens (OD reading of the sera of
the fourth injection was at saturation at 1:200 dilution),
and terminating bleeds were performed. The sera were
collected as mentioned above and stored at -80°C.
Competitive indirect ELISA
Two 96-well plates were each coated with 5 μg per well of
CL or SM2 artificial antigen overnight at 4°C. The plates
were washed 3 times with PBST, and blocked with 150 μl
of 0.1% (w/v) OVA per well at 37°C for 1.5 h. A 1:12,800
dilution of the antisera were shown during tittering to
achieve an OD in the working range, thus for both CL and
SM2, 50 μl of a 1:12,800 dilution of the corresponding
antiserum were applied to each well, and 50 μl of the cor-
responding hapten standard solutions was added as the
"competitor". The concentrations of the standard solu-
tions of CL were 0, 1, 5, 10, 20, 50, 100, 1000, 5000,
12,500, and 25,000 ng/ml; for SM2, the concentrations of
the standard solutions were 0, 1, 10, 50, 100, 1000, 5000,
10,000 and 20,000 ng/ml. Each concentration was added
to one row of twelve wells. The plates were incubated atZhong et al. BMC Biotechnology 2010, 10:12
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37°C for 1 h, and were processed the same way as in the
indirect ELISA mentioned above.
Protein microarray immunodetection
Twenty nanogram of each artificial antigen were spotted
onto a 7 × 7 array on P-L-L microarray slides (CapitalBio
Corporation, Beijing, China) using an OmniGrid-100
Microarrayer (Genomic Solutions, Ann Arbor, MI, USA).
Following a 2 h incubation in a humid chamber at 37°C,
the slides were inverted and immersed into PBS (pH 7.5)
containing 0.2% OVA (w/v). The slides were then turned
right side up and immersed in a 2% BSA solution for 1 h
at room temperature with gentle agitation. Next, the
slides were washed twice (10 s each) at room temperature
with PBST and twice with ddH2O. The diluted antiserum
(1:500 with PBS) and one of the corresponding standard
hapten solutions (0, 5, 10, 20, 50, 100 and 1000 ng/ml)
were mixed and added to an artificial antigen-spotted
protein microarray slide. The slides were incubated with
the antiserum-hapten mix for 1 h at room temperature
and then washed three times with PBST and once with
ddH2O. Then, cy3-goat-anti-rabbit IgG (1:4000 diluted in
PBST) was applied to the slides. After 1 h of incubation,
the slides were rinsed with PBST and then washed as pre-
viously. The slides were dried by centrifugation and
scanned using an Axon GenePix® 4000B microarray scan-
ner (Molecular Devices, Sunnyvale, CA, USA) to detect
the fluorescence signal.
IC50 determination
A dose-response curve was produced and was used to
calculate the IC50 by non-linear regression analysis using
GraphPad Prism 5 software (GraphPad Software, Inc, La
Jolla, CA, USA) For the ci-ELISA, the final optical density
reading was adjusted for background absorbance (OD =
OD450 nm - OD630 nm). The log of the hapten concentra-
tions were plotted against the percentage of inhibition,
which was calculated by the equation (ODsample/ODcontrol)
× 100%, where the control group (i.e., 0 ng/ml hapten)
OD was considered to be the point of 100% activity.
The results of the protein microarray assays were
reported as the average pixels of fluorescence at 532 nm
of the 49 spots for each hapten concentration minus
background pixels. The IC50 of the protein microarray
assays were determined by the same method of non-lin-
ear regression analysis as for the ci-ELISA.
Fortification of muscle homogenate with clenbuterol
The muscle tissue samples in control group were used in
the fortification studies. Fortification was carried out by
adding 25 μl of methanolic solutions containing clen-
buterol concentrations of 30, 120 and 300 ng/ml to the
tissue homogenate, resulting in fortification levels of 0.5,
2 and 5 ng/g, respectively [12,13]. The fortified samples
were used for calculation of recovery by ci-ELISA and
protein microarrays.
Preparation of muscle samples from clenbuterol-fed 
chicken
Fifteen eight-week-old broilers (AA species, Zhengda
Co., Beijing, China) were randomly divided into five
groups and raised in brooders provided with fresh feed
and water every day. The control group was given drug-
free feed; the other four groups were given feed treated
with 3 mg/kg CL (w/w) [12-14]. The broilers were fed for
14 consecutive days. One treated group was slaughtered
after 0, 1 day, 7 days, and 14 days withdrawal periods,
respectively. The muscle tissue samples were collected
and frozen at -20°C until analysis. The muscle tissue sam-
ples were homogenized using a DI 25 basic Ultraturrax
homogenizer (Ika-Werke, Staufen, Germany). Five gram
of homogenate was mixed with 25 ml 50 mM HCl by
shaking for 1.5 h. The homogenate was centrifuged, and
the supernatant was collected in a tube containing 300 μl
of 1 M NaOH and mixed for 15 min. 400 μl of 0.5 M
KH2PO4 were then added and the mixture was stored at
4°C overnight. The next day the mixture was centrifuged
at 2750 g for 15 min, and the supernatant was purified by
RP-18 cartridges (Supelco, Bellefonte, PA, USA). Clen-
buterol was eluted with methanol from the purified
supernatant as described elsewhere [15]. The eluent was
collected by vacuum and the solvent was evaporated
under a nitrogen stream. Dried residue was redissolved in
400 μl of water, and 20 μl per well were analyzed by ci-
ELISA and per slide by protein microarray analysis. The
concentrations of the recovered CL were calculated
against a standard curve made with 0, 1, 5, 10, 25, 50, 100,
250, 500 and 1000 ng/ml CL solutions for both methods.
The total CL recovered were converted to and reported
as per gram of tissue.
Results and Discussion
Protein microarray and competitive indirect ELISA (ci-
ELISA) were carried out in parallel to compare their sen-
sitivities for the detection of the haptens. Figure 1 shows
the schematics of the two assays. The sensitivity was
determined by measuring the IC50 of the haptens in com-
petitively inhibiting the binding of the antisera to the
immobilized artificial antigens. A dose-response curve
was produced for each assay for the two haptens tested
and was used to calculate the IC50 by non-linear regres-
sion analysis (Figure 2A and 2B). The classic sigmoidal
fashion demonstrated the specificity of the antisera to the
immobilized ligands. The IC50 of the haptens measured
by ci-ELISA were 190.7 ng/ml for CL and 156.7 ng/ml for
SM2  with a standard error of logIC50  of 0.06611 and
0.1169, respectively. On the other hand, The IC50 of the
haptens measured by the protein microarray immunode-
tection were 39.6 ng/ml for CL and 48.8 ng/ml for SM2
with a standard error of logIC50 of 0.06247 and 0.06494,Zhong et al. BMC Biotechnology 2010, 10:12
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Schematics of the ci-ELISA and protein microarray procedures
Figure 1 Schematics of the ci-ELISA and protein microarray procedures. 5 μg of the artificial antigens (CL or SM2) are coated onto the 96-well 
plates in (A) ci-ELISA, or 20 ng of the artificial antigens were spotted onto the protein microarray slides in (B) protein microarray. Antibodies against 
the particular artificial antigens are added together with a range of concentration of the corresponding hapten. As the haptens would compete with 
the immobilized artificial antigens for binding to the antisera, an increasing concentration of the hapten would result in a decreasing signal. For ci-
ELISA, the bound antibodies are visualized by an anti-rabbit-HRP conjugated antibody with the addition of a chromogen (A). For the protein array, the 












Table 1: Recoveries of CL from fortified chicken muscle tissues by ci-ELISA and protein microarray
CL added (ng/g) ci-ELISA Microarray
CL detected
(ng/g)
Recovery (%) CL detected
(ng/g)
Recovery (%)
0.5 0.38 ± 0.04 76 ± 7.8 0.45 ± 0.05 90* ± 9.9
2.0 1.54 ± 0.20 77 ± 9.9 1.84 ± 0.17 92* ± 8.5
5.0 4.25 ± 0.28 85 ± 5.6 4.50 ± 0.41 95 ± 8.6
Each experiment was repeated 5 times. *p < 0.05 by unpaired t-test.
% recovery = (CL detected/CL added) × 100%Zhong et al. BMC Biotechnology 2010, 10:12
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Table 2: Detection of CL from CL-treated chicken muscle tissues by ci-ELISA and protein microarray
Withdrawal Time (day) Detected CL ± SD (ng/g)
ci-ELISA Microarray
0 45 ± 3 48 ± 2
14  ±  1 . 2 7  ±  1 . 5
7 1 ± 0.3 3 ± 0.5*
14 0.1 ± 0.04 0.9 ± 0.03**
Each experiment was repeated 3 times. *p < 0.05 and **p = 0.0001 by unpaired t-test.
IC50 of protein microarray immuntodetection and ci-ELISA
Figure 2 IC50 of protein microarray immuntodetection and ci-ELISA. Upper panels: Dose-response curves for (A) CL and (B) SM2 from ci-ELISA and 
protein microarray. The log of the hapten concentration (x-axis) was plotted against the percentage of inhibition (y-axis), which is (ODsample/ODcontrol) 
× 100%. The control group OD was considered to be the point of 100% activity. The IC50 was determined by non-linear regression analysis. Lower 
panels: fluorescent signals from the protein microarray slides for (C) CL and (D) SM2. The concentration of the standard solution for each slide is: 1: 0 
ng/ml; 2: 1 ng/ml; 3: 5 ng/ml; 4: 10 ng/ml; 5: 20 ng/ml; 6: 100 ng/ml; 7: 1000 ng/ml.
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respectively. The scans of the microarray slides were
shown in Figure 2C and 2D. The protein microarrays
showed 4.5 and 3.5 times lower IC50 than the ci-ELISA
detection for CL and SM2 respectively, suggesting that the
protein microarray method has better sensitivity than the
ci-ELISA detection method.
We next examined if the protein microarray assay
would perform equally well with complex biological
material. Chicken muscles fortified with known concen-
trations of CL were homogenized, and the eluted CL
from each sample was being tested by the protein
microarray and ci-ELISA. As shown in Table 1, both
assays could recover effectively from the 5 ng/g CL-forti-
fied tissues. However, when the fortifying CL concentra-
tion was reduced to 2 and 0.5 ng/g, the protein
microarray could recover significantly more than ci-
ELISA (~90% vs. ~76%). When we examined the recovery
from CL-fed chicken muscle tissues, the protein microar-
ray assay again showed higher sensitivity than ci-ELISA
for samples with lower CL concentrations, i.e., longer
withdrawal periods (7 days and 14 days) (Table 2).
The use of DNA microarrays [16] and immunobiosen-
sor technology [17] in residue detection has become
increasingly popular in recent years. However, the use of
protein microarray technology for detecting toxic drug
residue in food is relatively new. Our study established
the use of protein microarray immunodetection of drug
residues as a better method than a traditional method
such as ci-ELISA. In our experiments, ci-ELISA underes-
timated the presence of CL in tissues when the concen-
tration was below the ng/g range. The protein microarray
displayed much more consistent recovery and higher sen-
sitivity. The fluorescence nature of the readout method of
the protein microarray is certainly more sensitive than
the colorimetric measurement in ci-ELISA. Moreover,
the measurement by protein microarray is more accurate
and reliable, as each sample can be assayed in much
higher number of repeats (49 spots on the microarray vs.
12 wells in ci-ELISA). The protein microarray method
also consumed far less samples than ci-ELISA. Thus, the
protein microarrays have the added advantages of requir-
ing fewer reagents, a faster analysis and the potential to
be a multi-analyte platform.
Conclusions
Our study has shown that protein microarray technology
is a more sensitive, reliable and efficient method for small
molecule detection than traditional ELISA.
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